The Transparency Paradox: Why Publishing Prices Can Raise Them
The case for hospital price transparency rests on a model of market competition that most hospital markets do not resemble. ...
The Payer Mix Problem: Why Hospital Prices Mean Something Different Depending on Who’s Asking
A hospital's published negotiated rate for a hip replacement is not a price. It is a price-per-payer, averaged across the ...
Original Sourcing in Health Journalism Is Broken. Price Data Might Help.
───────────────────────────────────────────────────────── The sentence "a new study finds" has become health journalism's most reliable crutch—and its most dangerous one. There is ...
What Price Transparency Law Actually Produced—and What It Didn’t
The rule was written to empower patients. It has, instead, mostly empowered analysts. The CMS Hospital Price Transparency Rule, which ...
The Price Database That Reporters Keep Ignoring
Hospital price transparency was supposed to change everything—and in the newsrooms that cover health policy, it has changed almost nothing. ...
Drug Pricing Transparency in an Era of Political Polarization: What MedPricer’s Data Reveals About a Contested Policy Landscape
Drug pricing data does not resolve policy debates—it sharpens them. When cross-benchmark analysis reveals that manufacturer list prices have increased ...
How To Better Support Stressed Adults Who Have ADHD
Adults with ADHD often experience challenges that extend beyond attention, including strain on work, relationships, and daily functioning. Symptoms can ...
Pharmaceutical Data Licensing and the Institutional Market: Who Would Pay for MedPricer’s Dataset and Why
Data businesses in healthcare have historically underpriced their products relative to the value they generate, either because the buyers are ...
When Market Signals Are Ambiguous: The Interpretive Limits of Cross-Benchmark Drug Pricing Analysis
A widening spread between WAC and ASP is consistent with at least four distinct mechanisms: increasing PBM rebates for formulary ...
Medicaid Drug Rebates and the NADAC Baseline: What State Policy Makers Are Missing
Medicaid drug reimbursement policy is set by state agencies operating under federal minimum standards, with the specific details of dispensing ...
The Gross-to-Net Compression Dashboard in Practice: How Investors Would Actually Use It
The practical challenge for pharmaceutical equity analysts is not understanding the gross-to-net concept—it is getting systematic, time-series data that allows ...
The Generic Drug Supply Chain and What Pricing Benchmarks Reveal About Its Fragility
Generic drug shortages in the United States are a recurring feature of the pharmaceutical landscape—not anomalies but predictable consequences of ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more